Biomarkers for mitochondrial disease
Signalling lipids serve as biomarkers for accurately assessing mitochondrial disease severity and treatment efficacy, addressing the need for reliable diagnostic methods and enabling personalized treatment strategies.
WO2026139605A2PCT designated stage Publication Date: 2026-07-02KHONDRION IP
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- KHONDRION IP
- Filing Date
- 2025-12-24
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
There is a need for improved diagnostic methods related to mitochondrial diseases, specifically for reliable biomarkers that allow for accurate diagnosis, monitoring of disease progression, and assessment of treatment efficacy.
Method used
The use of signalling lipids, such as 15-HETE, 5-HETE, 15-HETrE, 5-HETrE, and 12-13-DiHOME, as biomarkers to assess mitochondrial disease severity by determining their amounts in samples from subjects and comparing them to reference values.
Benefits of technology
Provides surprisingly accurate assessment of mitochondrial disease severity and treatment efficacy, correlating biomarker levels with clinical scales like NMDAS, enabling personalized treatment approaches.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000004_0001 
Figure IMGF000014_0001 
Figure IMGF000022_0001
Abstract
The invention relates to biomarkers for mitochondrial disease. Signalling lipids were identified as having good correlations with disease severity. Several of these biomarkers were found to correlate with treatment efficacy. Signalling lipids such as 15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid showed a positive correlation with disease severity and showed a corresponding decrease after treatment of the disease.
Need to check novelty before this filing date? Find Prior Art